Serengen
Serengen GmbH is a Dortmund-based biotech services company that designs and screens custom DNA-Encoded Libraries for pharmaceutical, biotechnology, and academic clients to accelerate unbiased hit identification in early drug discovery.
- Company typePrivate
- Founded2019
- HeadquartersDortmund, Germany
- Headcount1–10
- GTM typeB2B
- OfferingServices
What Serengen does
Serengen GmbH is a Dortmund-based biotech services company founded in summer 2019 that commercializes proprietary DNA-Encoded Library (DEL) technology originally developed at the Technical University of Dortmund. The company synthesizes and screens custom DELs for pharmaceutical companies, biotechnology firms, and academic/research organizations seeking faster and more economical unbiased hit identification in early-stage drug discovery.
Its core offering comprises two integrated services: customised DEL synthesis (delivered in three design modes — diversity-focused unbiased, target-focused structure-enabled, and hit-expansion ligand-enabled) and DEL selection screening using affinity matrix screening with enrichment calculation and double-control methodology. The underlying technology is differentiated by a novel encoding strategy based on stabilised DNA, a Double Fidelity System that removes by-products and reduces false positives/negatives, and limitation-free DNA-compatible chemistry intended to produce truly druglike, tractable hits that can be fed directly into lead generation.
Serengen operates as a B2B professional services company using direct enterprise sales, content marketing, and industry conferences (e.g., BIO-Europe 2023). Pricing is not publicly disclosed and is negotiated per project, with the company signalling "flexible business models." In August 2023, Serengen entered a strategic partnership with Deargen to add AI-driven drug-target interaction prediction (DearDTI) to its workflow. The company is privately held, has no disclosed external funding rounds or patents in the source data, and operates with a team of approximately five.
Serengen firmographics
Firmographics- Name
- Serengen
- Legal name
- Serengen GmbH
- Website
- https://serengen.com
- Company type
- Private
- Founded year
- 2019
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Serengen GmbH is a Dortmund-based biotech services company that designs and screens custom DNA-Encoded Libraries for pharmaceutical, biotechnology, and academic clients to accelerate unbiased hit identification in early drug discovery.
- Ownership category
- akta.pro rank
Serengen industry classification
Industry- Product category
- Drug Discovery Services
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Library & Diversity Generation Platforms (display libraries, DNA-encoded libraries for biologics, variant libraries) (HLAAAIAL)
- akta.pro secondary industry
- AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening) (HLAAAIAE)
Keywords
Where Serengen is headquartered
LocationHeadquarters
- HQ city
- Dortmund
- HQ country
- Germany
- HQ region
- Europe
Offices1 record
Markets served
Serengen business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales
Revenue model
- Customised DEL Synthesis: Serengen synthesises DNA-Encoded Libraries tailored to individual drug discovery projects, offering unbiased design (diversity-focused DEL), structure-enabled design (target-focused DEL), and ligand-enabled design (hit-expansion DEL).
- DEL Selection Screening: Provides affinity matrix screening services with enrichment calculation and double control for a wide range of proteins including membrane-bound proteins, PPIs, enzymes, and transcription factors.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels3 records
Serengen product offering
Product offeringCore offering
Serengen is a biotech company that synthesises and screens custom DNA-Encoded Libraries (DEL) for pharmaceutical, biotech, and research clients. Its proprietary limitation-free chemistry delivers druglike, tractable hits for early-stage drug discovery, enabling fast and cost-efficient unbiased hit identification.
Product overview
Serengen offers a unified DEL technology platform comprising two integrated services: Customised DNA-Encoded Library (DEL) Synthesis and DEL Selection Screening. Their proprietary technology overcomes traditional DEL limitations by enabling limitation-free chemistry that delivers truly druglike, tractable hits. The platform supports unbiased design (diversity-focused DEL), structure-enabled design (target-focused DEL), and ligand-enabled design (hit-expansion DEL) for diverse molecular classes including small molecules, short peptides, peptidomimetics, and macrocycles, targeting membrane-bound proteins, PPIs, enzymes, and transcription factors.
Differentiator
Problem solved
Functional benefit
Products and services
- Customised DNA-Encoded Library (DEL) Synthesis Custom synthesis of DNA-Encoded Libraries tailored to individual drug discovery projects using limitation-free chemistry to deliver druglike, tractable hits that feed directly into lead generation. Supports unbiased (diversity-focused), structure-enabled (target-focused), and ligand-enabled (hit-expansion) DEL design for pharma, biotech, and research organisations.
- DEL Selection Screening Unbiased DEL screening service using affinity matrix screening across a wide range of proteins including membrane-bound proteins, PPIs, enzymes, and transcription factors, with enrichment calculation and double-control methodology to identify high-quality hits.
Quantifiable outcome
- Low hit-to-lead attrition rate due to truly druglike tractable hits
Companies that use Serengen
Customer profileSegments3 records
Ideal customer profiles3 records
Serengen technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability1 record
Feature5 records
Serengen partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- DeargencoreStrategic partnership integrating Serengen's novel DNA-Encoded Library (DEL) technology with Deargen's AI-driven drug discovery platform (DearDTI). The collaboration aims to accelerate drug discovery by combining DEL technology with Artificial Intelligence, enhancing efficiency and success rates in drug development. Both companies share the goal of offering valuable insights to clients and seeking innovative drug discovery solutions.
Scale indicators2 records
Recent moves5 records
Expansion highlights5 records
Serengen competitors and assessment
Company assessmentMarket position
Competitive moat3 records
Key risks5 records
Key highlights5 records
Customer concentration
Serengen social profiles
Digital presenceSerengen financial estimates
Financial estimateRevenue estimate
Valuation estimate
Serengen leadership team
Management profileNumber of profiles
Profiles2 records
Serengen funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Serengen M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Serengen
What does Serengen do?
Serengen is a biotech company that synthesises and screens custom DNA-Encoded Libraries (DEL) for pharmaceutical, biotech, and research clients. Its proprietary limitation-free chemistry delivers druglike, tractable hits for early-stage drug discovery, enabling fast and cost-efficient unbiased hit identification.
Is Serengen a public or private company?
Serengen is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Serengen founded?
Serengen was founded in 2019. It employs 1 to 10 people.
Where is Serengen based?
Serengen is headquartered in Dortmund, Germany, in the Europe region.
How does Serengen make money?
Two revenue lines are on record. Customised DEL Synthesis are the primary driver. The others are DEL Selection Screening.
Does Serengen have an API?
No public API is recorded for Serengen.
What industry is Serengen in?
Serengen's product category is Drug Discovery Services. Its primary akta.pro industry code is HLAAAIAL, Library & Diversity Generation Platforms (display libraries, DNA-encoded libraries for biologics, variant libraries), with a secondary code of HLAAAIAE, AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening). Its NAICS code is 541714 and its SIC code is 8731.